Table 1.
Compounda | Range-finder performed | MTD achieved (no, yes, exceeded) | Endpoint that was used to select dose levels | No. of dose levelsb |
---|---|---|---|---|
1 | Yes | Yes | Body weight | 3 |
2 | Yes | No | Kidney pathology | 3 |
3 | Yes | No | Clinical signs | 3 |
4 | Yes | Yes | Body weight | 3 |
5 | No | Yes | Cholinesterase inhibition | 4 |
6 | Yes | Yes | Body weight | 4 |
7 | Yes | Yes | Liver weight | 3 |
8 | No | No | Clinical signs | 3 |
9 | Yes | Yesc | Clinical signs | 3 |
10 | No | Yesd | Limit dose (1000 mg/kg) | 3 |
14 | Yes | Yes | Clinical signs/body weight | 4 |
15 | Yes | Yes | Creatinine increases | 4 |
16 | Yes | Yes | Cholinesterase inhibition | 4 |
17 | Yes | Yes | Hepatocellular necrosis | 4 |
18 | Yes | Yes | Body weight | 4 |
19 | Yes | Yes | Body weight | 4 |
20 (assay #1) | Yes | Exceeded | Body weight | 4 |
20 (assay #2) | Yes | Yes | Body weight | 4 |
21 | No | Yese | Cholinesterase inhibition | 3 |
22 | No | Yese | Cholinesterase inhibition | 3 |
23 | Yes | Yes | Clinical signs | 3 |
Test materials were arbitrarily assigned a “compound number,” which is consistent between this table and Table 2.
Number of dose levels evaluated including controls in the male pubertal assay.
Dose levels selected to avoid systemic toxicity that was observed at slightly higher dose levels in previous studies.
Maximum tolerated dose was achieved since testing was done at limit dose of 1000 mg/kg.
Maximum tolerated dose selected using read across to previously performed studies.